comprehensive -WSS

comprehensive

author：fashion 2025-09-29 01:37:56 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： Focused ultrasound for uterine fibroids: an uphill battle

knowledge

hotspot

entertainment

WSS

Startling documents reveal new facets of Sacklers' opioid empire

Scientists successfully use ultrasound imaging to map brain activity

Scientists successfully use ultrasound imaging to map brain activity

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

ADA: All diabetes patients should be screened for liver condition

Wikipedia

comprehensive

knowledge

Continuity nursing helped my family in our darkest PICU moments

David Sabatini, ex

Apple is now the first public company to be valued at $3 trillion

iTeos Therapeutics debuts first data on TIGIT

Jerome Adams on the need for new antivirals for Covid

ADA: All diabetes patients should be screened for liver condition

Medicare details structure of new drug price negotiation program

Adam's Biotech Scorecard: Do Sarepta's exon

Anesthesiologist group: stop taking Ozempic before surgery

Biohaven protein

entertainment

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Here's how to stay safe from wildfire smoke amid reduced air quality

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Lab trade group sues FDA to halt regulation of lab

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

knowledge

hotspot

entertainment

entertainment